翻訳と辞書 |
Synageva Synageva BioPharma Corp. was a publicly listed biopharmaceutical company () headquartered in Lexington, Massachusetts dedicated to discovering, developing and delivering medicines for patients with rare diseases and high unmet medical needs. The company had manufacturing and laboratory locations in Lexington and Holden, Massachusetts, Bogart and Athens Georgia, as well as offices in a variety of locations around the world. ==History== Synageva was formed when Sanj K. Patel (formerly an executive at Genzyme Corporation, Cambridge, Massachusetts) was approached in early 2008 by Baker Bros. Investments to be the CEO of privately held Avigenics, Inc. in Athens, Georgia, a company initially formed by Dr. Robert Ivarie of the University of Georgia.〔Lee Shearer (April 21, 2014). "UGA BioBusiness Center helps turn discoveries into companies". Athens Banner-Herald. Retrieved May 8, 2015.〕 Upon joining AviGenics in June 2008, Mr. Patel created the vision and strategy for Synageva and changed the company’s direction to focus on products for the treatment of devastating, rare diseases. This represented a substantial shift in the original company’s business strategy of developing bio-similar drugs using its novel egg white (EW) protein production technology. The company’s proprietary technology produces proteins by recombinant DNA technology in egg white (EW) using a transgenic Gallus expression system. The proteins are then purified using conventional recombinant protein chromatographic methods. The EW system can consistently express proteins that contain glycan structures, predominantly GlcNAc- and mannose-terminated N-linked glycan structures, as well as mannose-6-phosphate (M6P) glycans, which are specifically recognized and internalized via receptors into key target cells. With the support from a dedicated and experienced team, Synageva went public on the NASDAQ Global Market in November 2011 by completing a reverse merger with Trimeris, Inc. Synageva later relocated its corporate headquarters to Lexington, Massachusetts. On May 6, 2015, Alexion Pharmaceuticals () and Synageva announced that they entered into a definitive agreement in which Alexion would acquire Synageva for a value of $230 per share.〔Alexion Press Release. (2015). “Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases”. 〕 The transaction was unanimously approved by both companies’ Boards of Directors, and is valued at approximately $8.4 billion net of Synageva’s cash (total $9.1 billion). This was the one of the largest premiums paid to any company over $5 billion in market cap since 1995.〔Peter Loftus, Jonathan D. Rockoff and Maureen Farrell (May 6, 2015). “Alexion-Synageva Deal Shows Lure of Rare-Disease Drugs”. The Wall Street Journal. 〕
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Synageva」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|